$134.982,00
10% de descuento pagando con Transferencia
Ver más detalles
Descripcion
Indice
Autores
Muestra
Ficha Técnica
Descripción

In this issue, guest editors bring their considerable expertise to this important topic.

  • Provides in-depth reviews on the latest updates in the field, providing actionable insights for clinical practice
  • Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field
  • Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews

1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. CME Accreditation Page - p. xiii 8. Preface - p. xv 9. Facts and Fictions About [18F]FDG versus Other Tracers in Managing Patients with Brain Tumors: It Is Time to Rectify the Ongoing Misconceptions - p. 327 10. An Appraisal and Update of Fluorodeoxyglucose and Non-Fluorodeoxyglucose-PET Tracers in Thyroid and Non–Thyroid Endocrine Neoplasms - p. 343 11. 18F-Fluorodeoxyglucose-PET-Computerized Tomography and non-Fluorodeoxyglucose PET-Computerized Tomography in Hepatobiliary and Pancreatic Malignancies - p. 369 12. Molecular Imaging Assessment of Androgen Deprivation Therapy in Prostate Cancer - p. 389 13. Molecular Imaging Assessment of Hormonally Sensitive Breast Cancer: An Appraisal of 2-[18F]-Fluoro-2-Deoxy-Glucose and Newer Non-2-[18F]-Fluoro-2-Deoxy-Glucose PET Tracers - p. 399 14. 18F-FDG Versus Non-FDG PET Tracers in Multiple Myeloma - p. 415 15. Role of Molecular Imaging with PET/MR Imaging in the Diagnosis and Management of Brain Tumors - p. 431 16. Fibroblast Activation Protein Inhibitor Theranostics - p. 453 17. PET-CTBased Quantitative Parameters for Assessment of Treatment Response and Disease Activity in Cancer and Noncancerous Disorders - p. 465 18. Positron Emission Tomography-Based Assessment of Cognitive Impairment and Dementias, Critical Role of Fluorodeoxyglucose in such Settings - p. 479 19. Nonmalignant Thoracic Disorders: An Appraisal of Fluorodeoxyglucose and Non-fluorodeoxyglucose PET/Computed Tomography Applications - p. 495 20. Fluorodeoxyglucose PET/Computed Tomography in Evaluation of Prosthetic Joints and Diabetic Foot: A Comparative Perspective with Other Functional Imaging Modalities - p. 517 21. Utility of PET/Computed Tomography in Infection and Inflammation Imaging - p. 533 22. Role of Fluorodeoxyglucose-PET in Interventional Radiology - p. 543

Descripcion
Descripción

In this issue, guest editors bring their considerable expertise to this important topic.

  • Provides in-depth reviews on the latest updates in the field, providing actionable insights for clinical practice
  • Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field
  • Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews

1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. CME Accreditation Page - p. xiii 8. Preface - p. xv 9. Facts and Fictions About [18F]FDG versus Other Tracers in Managing Patients with Brain Tumors: It Is Time to Rectify the Ongoing Misconceptions - p. 327 10. An Appraisal and Update of Fluorodeoxyglucose and Non-Fluorodeoxyglucose-PET Tracers in Thyroid and Non–Thyroid Endocrine Neoplasms - p. 343 11. 18F-Fluorodeoxyglucose-PET-Computerized Tomography and non-Fluorodeoxyglucose PET-Computerized Tomography in Hepatobiliary and Pancreatic Malignancies - p. 369 12. Molecular Imaging Assessment of Androgen Deprivation Therapy in Prostate Cancer - p. 389 13. Molecular Imaging Assessment of Hormonally Sensitive Breast Cancer: An Appraisal of 2-[18F]-Fluoro-2-Deoxy-Glucose and Newer Non-2-[18F]-Fluoro-2-Deoxy-Glucose PET Tracers - p. 399 14. 18F-FDG Versus Non-FDG PET Tracers in Multiple Myeloma - p. 415 15. Role of Molecular Imaging with PET/MR Imaging in the Diagnosis and Management of Brain Tumors - p. 431 16. Fibroblast Activation Protein Inhibitor Theranostics - p. 453 17. PET-CTBased Quantitative Parameters for Assessment of Treatment Response and Disease Activity in Cancer and Noncancerous Disorders - p. 465 18. Positron Emission Tomography-Based Assessment of Cognitive Impairment and Dementias, Critical Role of Fluorodeoxyglucose in such Settings - p. 479 19. Nonmalignant Thoracic Disorders: An Appraisal of Fluorodeoxyglucose and Non-fluorodeoxyglucose PET/Computed Tomography Applications - p. 495 20. Fluorodeoxyglucose PET/Computed Tomography in Evaluation of Prosthetic Joints and Diabetic Foot: A Comparative Perspective with Other Functional Imaging Modalities - p. 517 21. Utility of PET/Computed Tomography in Infection and Inflammation Imaging - p. 533 22. Role of Fluorodeoxyglucose-PET in Interventional Radiology - p. 543

Indice
Autores
Muestra
Ficha Técnica